The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Dysfunctional HDL and atherosclerotic cardiovascular disease
Open accessAbstract
High-density lipoproteins (HDLs) protect against atherosclerosis by removing excess cholesterol from macrophages through the ATP-binding cassette transporter A1 (ABCA1) and ATP-binding cassette transporter G1 (ABCG1) pathways involved in reverse cholesterol transport. Factors that impair the availability of functional apolipoproteins or the activities of ABCA1 and ABCG1 could, therefore, strongly influence atherogenesis. HDL also inhibits lipid oxidation, restores endothelial function, exerts anti-inflammatory and antiapoptotic actions, and exerts anti-inflammatory actions in animal models. Such properties could contribute considerably to the capacity of HDL to inhibit atherosclerosis. Systemic and vascular inflammation has been proposed to convert HDL to a dysfunctional form that has impaired antiatherogenic effects. A loss of anti-inflammatory and antioxidative proteins, perhaps in combination with a gain of proinflammatory proteins, might be another important component in rendering HDL dysfunctional. The proinflammatory enzyme myeloperoxidase induces both oxidative modification and nitrosylation of specific residues on plasma and arterial apolipoprotein A-I to render HDL dysfunctional, which results in impaired ABCA1 macrophage transport, the activation of inflammatory pathways, and an increased risk of coronary artery disease. Understanding the features of dysfunctional HDL or apolipoprotein A-I in clinical practice might lead to new diagnostic and therapeutic approaches to atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some studies have indicated a complete loss of function and dysfunction gain concerning anti-inflammatory, vasodilatory, and antiapoptotic activities.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“However, there are instances where HDL’s ability to deliver cholesterol esters via SCARB1 may be reduced, indicating only a partial loss of function.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“It was noted that HDL could lose its anti-inflammatory properties and even develop proinflammatory characteristics.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“However, when it comes to antioxidative activity and cholesterol efflux capacity, the deficiency observed in HDL’s normal function falls short of complete dysfunction [9].”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Subsequent research has shown that the extent of HDL’s normal function loss and dysfunction gain can vary depending on its different biological activities.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Dysfunctional HDL (dys-HDL) are HDL cholesterol particles with high pro-atherogenic characteristics, characterized by the loss of typical antioxidant properties, becoming carriers of oxidized lipids themselves.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
In the citing paper
“Moreover, modulations in HDL particle composition can transform it to dysfunctional and, through this modulation, increase the risk of CVD40.”
From Prolonged sleep restriction induces changes in pathways involved in cholesterol metabolism and inflammatory responses (2016) · cites this paper as [40]
In the citing paper
“Decrease in HDL has been regarded as one important risk factor for cardiovascular diseases40.”
From Prolonged sleep restriction induces changes in pathways involved in cholesterol metabolism and inflammatory responses (2016) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Self-citationEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationWiller (2013) · doi:10.1038/ng.2797 · Cited by 2,983
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Self-citationCholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Large-scale association analysis identifies new risk loci for coronary artery disease
The CARDIoGRAMplusC4D Consortium, Deloukas, P., DIAGRAM Consortium, CARDIOGENICS Consortium, MuTHER Consortium, Wellcome Trust Case Control Consortium, Kanoni, S., Willenborg, C., Farrall, M., Assimes, T. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2480 · Cited by 1,614
HDL cholesterol efflux capacity and incident cardiovascular events
Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., Neeland, I. J., Yuhanna, I. S., Rader, D. R., de Lemos, J. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409065 · Cited by 1,390
Daugherty, A., Dunn, J. L., Rateri, D. L., & Heinecke, J. W. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117342 · Cited by 1,269
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 821
Impact of Antioxidant and Anti-Inflammatory Functions of HDL in Diseases—2nd Edition
Cervellati, C., & Marsillach, J. (2025) · Antioxidants · doi:10.3390/antiox14030358 · Cited by 4
Li, C., Wu, J., Zhang, Y., He, H., Hu, Y., Wei, J., Lei, G., & Zeng, C. (2025) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2025.07.013 · Cited by 4
Nakada, K., Tanaka, K., Kimura, H., Saito, H., Oda, A., Watanabe, S., Shimabukuro, M., Asahi, K., Watanabe, T., & Kazama, J. J. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005581 · Cited by 4
Qiu, Z., Wang, R.-Y., Zhang, Y., Huang, H.-B., He, R.-Y., Yan, H., Luo, P., Yang, B., Xu, Z.-F., & He, Q.-J. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01729-x · Cited by 6
Na, J., Huang, L., Wang, L. J., Ni, Y., Chen, Y., Luo, Q., & Li, Y. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124209 · Cited by 4
Sergi, D., Sanz, J. M., Trentini, A., Bonaccorsi, G., Angelini, S., Castaldo, F., Morrone, S., Spaggiari, R., Cervellati, C., & Passaro, A. (2024) · Nutrients · doi:10.3390/nu16101525 · Cited by 5
PON1 and PON3 in Alzheimer’s Disease: Similar Functions but Different Roles
Trentini, A., Rosta, V., Riccetti, R., Mola, G., Galletti, R., Pinotti, M., Senia, V., Zuliani, G., & Cervellati, C. (2024) · Antioxidants · doi:10.3390/antiox13101216 · Cited by 5
Wierzbicki, A. S. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2444986 · Cited by 8
Liu, Y., Xu, M., Wang, L., Li, M., Li, M., & Mu, S. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02446-4 · Cited by 6
Bahbah, E. I., Shehata, M., Alnahrawi, S. I., Sayed, A., Menshawey, A., Fisal, A., Morsi, M., Gabr, M. E., & Elbasit, M. S. A. (2021) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2021.102282 · Cited by 4
de la Cruz, S., Leon‐Acuña, A., Yubero‐Serrano, E. M., Torres-Peña, J. D., Larriva, A. P. A.-D., Cardelo, M. P., Rangel-Zúñiga, O. A., Luque, R. M., Alcala-Diaz, J. F., Ordovás, J. M., et al. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.06.002 · Cited by 4
Hypolipidemic effect and antioxidant properties of cassava-wheat flour composite bread in rats
Ajani, R. A., Adefegha, S. A., & Oboh, G. (2022) · Journal of Food Measurement & Characterization · doi:10.1007/s11694-022-01600-1 · Cited by 4
Li, Q.-X., Ma, X., Shao, Q., Yang, Z., Liang, J., Yang, L., Shi, D.-M., Zhou, Y.-J., & Wang, Z. (2022) · PubMed Central · doi:10.11909/j.issn.1671-5411.2022.12.001 · Cited by 4
Iyoda, T., Ohishi, A., Wang, Y., Yokoyama, M.-S., Kazama, M., Okita, N., Inouye, S., Nakagawa, Y., Shimano, H., & Fukai, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031825 · Cited by 4
Huang, Y., Li, Y., Wu, Z., Liang, Y., & He, J. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02346-z · Cited by 4
Lipid profile and risks of cardiovascular diseases in conditions of rheumatoid arthritis
Pašková, Ľ. (2019) · Česká a slovenská farmacie · doi:10.36290/csf.2019.027 · Cited by 13
Zhang, P., Mo, D.-G., Lin, F., & Dai, H. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04558-2 · Cited by 4
Yan, C., Zhen, Z., Shi, Y., Zhao, P., Song, X., Peng, Q., Wang, X., Zhou, W., Yu, C., Wang, T., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104026 · Cited by 4
MicroRNA-33 inhibition ameliorates muscular dystrophy by enhancing skeletal muscle regeneration
Sowa, N., Horie, T., Ide, Y., Baba, O., Kora, K., Yoshida, T., Nakamura, Y., Matsumura, S., Matsushita, K., Imanaka, M., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00273-9 · Cited by 4
Assessing cardiovascular risk in ATM heterozygotes
Kotchetkoff, E. C. D. A., de Souza, F. I. S., Fonseca, F. L. A., Hix, S., Ajzen, S., Shigueoka, D. C., Costa‐Carvalho, B. T., & Sarni, R. O. S. (2018) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.64.02.148 · Cited by 4
Atteintes macrovasculaires de la sclérodermie : état de la question en 2019
Bertolino, J., Scafi, M., Benyamine, A., Aïssi, K., Boufi, M., SCHLEINITZ, N., Sarlon, G., Rossi, P. M., & Granel, B. (2019) · JMV-Journal de Médecine Vasculaire · doi:10.1016/j.jdmv.2019.09.002 · Cited by 4
Song, B., Dai, D., Liu, S., Zhu, Z., Ding, F., Zhu, J., & Zhang, R. (2021) · Renal Failure · doi:10.1080/0886022x.2021.1880936 · Cited by 4
Vargas, J. I., Rivera, K., Arrese, M. A., Benítez, C., Francisco Barrera, M., Monrroy, H., Arab, J. P., Pino, K., Barrera, A., López‐Lastra, M., et al. (2021) · Annals of Hepatology · doi:10.1016/j.aohep.2021.100555 · Cited by 4
Azemi, N. A., Azemi, A. K., Abu-Bakar, L., Vigneswari, S., Muhammad, T. S. T., & Ismail, N. (2022) · Marine Drugs · doi:10.3390/md20120762 · Cited by 4
Hokstad, I., Greco, D., Deyab, G., Fagerland, M. W., Agewall, S., Hjeltnes, G., Zimetti, F., Bernini, F., Ronda, N., & Hollan, I. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247330 · Cited by 4
Namba, N., Ohgita, T., Tamagaki-Asahina, H., Nishitsuji, K., Shimanouchi, T., Sato, T., & Saito, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-45803-y · Cited by 4
He, S., Yu, C., Kuang, M., Qiu, J., Yang, R., Zhang, S., Sheng, G., & Zou, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1266692 · Cited by 4
Zheng, W., Zhang, J., Jiang, Y. H., Wang, S., & Yang, Z. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123624 · Cited by 4
Predictive value of plasma lipid levels for coronary artery disease (CAD)
Shahid, S. U., Shabana, N. A., & Rehman, A. (2020) · Biologia · doi:10.2478/s11756-020-00448-4 · Cited by 6
Pro-inflammatory HDL in women with obesity and nonalcoholic steatohepatitis
Sarkar, S., Tsuchida, Y., Diab, R. H., Xu, C., Yermalitsky, V. N., Davies, S. S., Ikizler, T. A., Hung, A. M., Kon, V., & Flynn, C. R. (2020) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2020.06.002 · Cited by 4
Hancock-Cerutti, W. F., Millar, J. S., Valentini, S., Liu, J., Billheimer, J. T., Rader, D. J., & Cuchel, M. (2021) · Molecules · doi:10.3390/molecules26226862 · Cited by 4
Apolipoprotein A1 distribution pattern in the human Achilles tendon
Gaida, J. E., Alfredson, H., Scott, A., Mousavizadeh, R., & Forsgren, S. (2018) · Scandinavian Journal of Medicine and Science in Sports · doi:10.1111/sms.13051 · Cited by 4
Phosphatidylethanolamine accelerates aggregation of the amyloidogenic N‐terminal fragment of apoA‐I
Kurimitsu, N., Mizuguchi, C., Fujita, K., Taguchi, S., Ohgita, T., Nishitsuji, K., Shimanouchi, T., & Saito, H. (2020) · FEBS Letters · doi:10.1002/1873-3468.13737 · Cited by 4
High-density lipoprotein: Quality versus quantity in type 2 diabetes mellitus
Bitla, A. R. R., Naresh, S., & Sachan, A. (2019) · The Journal of Clinical and Scientific Research · doi:10.4103/jcsr.jcsr_108_19 · Cited by 4
Vargas‐Alarcón, G., Avilés‐Jiménez, F., Mejía-Sánchez, F., Pérez‐Hernández, N., Cardoso-Saldaña, G. C., & Posadas‐Sánchez, R. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105719 · Cited by 4
HDL ‐Apolipoprotein in Alzheimer's Disease Revisited: From Periphery to CNS
Huang, Y., Tang, J., Chen, G., Wu, Q., Wang, Y., Chen, J., Chen, S., Liu, J., & Huang, X. (2025) · Aging Medicine · doi:10.1002/agm2.70008 · Cited by 3
Relationship of fractalkine with arsenic exposure and the risk of cardiovascular diseases
Uddin, N., Rimi, R. K., Goni, O., Mohanto, N. C., Rossi, K. N., Abedin, F., Beauty, S. A., Ahmed, B., Mia, S., Sarder, S. J., et al. (2025) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2025.104824 · Cited by 3
Zhang, P., Mo, D.-G., Dong, C., Zeng, W., Li, N., Wu, J., Wang, G., & Dai, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1701364 · Cited by 4
Inventive HDL Mimicking Nanoparticles: A Promising Frontier in Cardiovascular Disease Management
Ratra, S., Mukherjee, S., Ray, S., Yu, A., & Rengan, A. K. (2025) · Cardiovascular Toxicology · doi:10.1007/s12012-025-10074-8 · Cited by 4
Liu, J., Xu, H., Huang, C., Qiu, X., Lu, X., Weng, C., Wang, C., & Xu, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1741265 · Cited by 3
Boucher, D. M., Lorant, V., Rochon, V., Carter, A., Stotts, C., Nguyen, M.-A., Laval, T., Emerton, C., Joyce, N., Vinayak, N., et al. (2026) · Advanced Science · doi:10.1002/advs.202511121 · Cited by 3
Shahannaz, D. C., & Sugiura, T. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083617 · Cited by 3
Poteryaeva, O. N., & Федорович, У. И. (2022) · Russian Clinical Laboratory Diagnostics · doi:10.51620/0869-2084-2022-67-7-381-390 · Cited by 3
Comparison of Cell-based and Nanoparticle-based Therapeutics in Treating Atherosclerosis
Goh, W. X., Kok, Y.-Y., & Wong, C.-Y. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128272185231024115046 · Cited by 3
Namin, S. M., Moradi, A., Tavolinejad, H., Vasheghani‐Farahani, A., Jalali, A., Pashang, M., Sadeghian, S., Bagheri, J., Mansourian, S., Mehrani, M., et al. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-03806-1 · Cited by 3
Song, W., Chen, Y., Chen, X., Chen, J., Xu, Z., Gong, K.-Z., Wang, W., & Zhang, F.-L. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-081808 · Cited by 3
Guo, Y., Zhao, H., Zhao, J., Li, S., Meng, L., Li, J., Qian, Y., Li, Y.-L., Cui, B.-Y., Guo, S., et al. (2025) · European Journal of Nutrition · doi:10.1007/s00394-024-03578-6 · Cited by 3
Bonnin-Marquez, A., Jankowski, J., Maas, S. L., Hermann, J., Kahles, F., Lellig, M., Fliser, D., Schunk, S. J., Stamellou, E., Berger, M., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.02.010 · Cited by 3
Soler‐Espejo, E., Chen, Y., Rivera‐Caravaca, J. M., Ramos‐Bratos, M. P., Esteve‐Pastor, M. A., Marín, F. R., Roldán, V., & Lip, G. Y. H. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02927-x · Cited by 3
Further options for treating lipids in people with diabetes: targeting LDL ‐cholesterol and beyond
Wierzbicki, A. S. (2018) · Diabetic Medicine · doi:10.1111/dme.13667 · Cited by 3
Oxidized Lipoproteins as the Diagnostic Target for Cardiovascular Diseases
Sreeja, S., Manoharan, A., & Venkataraman, K. (2018) · Current Science · doi:10.18520/cs/v115/i7/1276-1286 · Cited by 2
Yagi, S., Furukawa, S., Miyake, T., Shiraishi, K., Tange, K., Hashimoto, Y., Kitahata, S., Ninomiya, T., Suzuki, S., Shibata, N., et al. (2022) · Digestion · doi:10.1159/000527353 · Cited by 3
Takata, K., Imaizumi, S., Iwata, A., Zhang, B., Kawachi, E., Miura, S., & Ogawa, M. (2023) · Biomolecules · doi:10.3390/biom13091278 · Cited by 3
Xu, Q., Fan, K., Wei, D., Wang, L., Wang, J., Song, Y., Wang, M., Zhao, M., Liu, X., Huo, W., et al. (2023) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2023.115524 · Cited by 3
Niu, Y., Wang, G., Feng, X., Niu, H., Shi, W., & Shen, Y. (2024) · Lipids · doi:10.1002/lipd.12385 · Cited by 3
A comprehensive analysis of the role of native and modified HDL in ER stress in primary macrophages
Bobek, J. M., Stuttgen, G. M., & Sahoo, D. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1448607 · Cited by 3
The functional subclasses of AT1 receptor autoantibody in patients with coronary heart disease
Yang, Z., Sun, T., Wang, P., Bai, L., Wu, Y., Wang, T., Li, X., Cheng, Y., Zhang, S., & Liu, H. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116546 · Cited by 3
Haidar, L., Bălteanu, M. A., Georgescu, M., Drăghici, G. A., Laza, E.-A., Serb, A. F., & Cioboată, R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237245 · Cited by 3
Identification of Novel Compounds Enhancing SR-BI mRNA Stability through High-Throughput Screening
Jia, X., Du, Y., Jiang, H.-J., Li, Y., Xu, Y., Si, S., Wang, L., & Hong, B. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219894543 · Cited by 3
Atherosclerosis, Arteriosclerosis and Arteriolosclerosis
Gianturco, L. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.83058 · Cited by 4
Extremely high high‐density lipoprotein cholesterol with coronary artery disease: Case report
Sawalha, K., & Kamoga, G. (2021) · Clinical Case Reports · doi:10.1002/ccr3.4092 · Cited by 2
The High Density Lipoprotein Cholesterol Hypothesis Revisited
Meiliana, A., Dewi, N. M., & Wijaya, A. (2018) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v10i2.465 · Cited by 2
Hernáez, Á., Valussi, J., Pérez‐Vega, K. A., Castañer, O., & Fitó, M. (2019) · Reference series in phytochemistry · doi:10.1007/978-3-319-78030-6_33 · Cited by 3
Investigation of dysfunctional HDL using myeloperoxidase / paraoxonase ratio in lymphoma
Neşeli̇oğlu, S., Pekcan, G., Gök, G., Yurt, E. F., & Erel, Ö. (2019) · Harran Üniversitesi Tıp Fakültesi Dergisi · doi:10.35440/hutfd.579011 · Cited by 3
Lau, S., & Middleton, D. A. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004130 · Cited by 3
Zhu, J.-N., Wang, Y., Li, M., Huang, D., Li, S., & Li, J. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04113-5 · Cited by 2
HMGB1 as a biomarker for myeloproliferative neoplasm complicated with atherosclerosis
Wu, L., Han, D., Zhang, X., Zhang, S., Wang, Y., Han, W., Jiang, B., Chen, H., & Jiang, L. (2025) · European journal of medical research · doi:10.1186/s40001-025-02655-8 · Cited by 2
Park, A., Fandl, H. K., Garcia, V. P., Berry, A. R., Wegerson, K. N., Ostrander, E. I., Cardenas, H. L., DeSouza, N. M., Greiner, J. J., Stauffer, B. L., et al. (2025) · Topics in Spinal Cord Injury Rehabilitation · doi:10.46292/sci24-00068 · Cited by 2
Liu, Y., Hu, O., Wang, Z., Wang, J., Qiu, Y., Xiao, J., Cheng, X., Yang, P., Xia, N., Xiong, Y., et al. (2025) · The Analyst · doi:10.1039/d5an00396b · Cited by 2
Ogura, M. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2569403 · Cited by 2
Lu, Z., Jian, G., Jiang, K., He, S., Wang, Z., Wang, J., Lan, H., Sheng, G., Zou, Y., & Zhang, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1667929 · Cited by 2
Sheashaa, H., Awad, K., Abbas, M. T., Farina, J., Pereyra, M., Scalia, I. G., Ali, N. B., Bismee, N. N., Esfahani, S. A., Ibrahim, O., et al. (2025) · Coronary Artery Disease · doi:10.1097/mca.0000000000001589 · Cited by 2
Arun, A. J., Kaneki, S., Baig, M., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001126 · Cited by 3
Chiu, P., Chou, H., Lin, C., Li, H., Chen, T., Chen, H., & Chang, H.-T. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01910-8 · Cited by 3
Otolith Deterioration: Factors Affecting Microvascular and Structural Integrity
Choi, E., Park, J., Kwon, H., Jung, I., Kim, H. J., Choi, J., & Kim, J. (2026) · Journal of Clinical Neurology · doi:10.3988/jcn.2025.0439 · Cited by 2
Insights to HDL dysfunctionality: hypothesis of exhausted HDL
Mahrooz, A. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113145 · Cited by 2
Fang, W., Zhao, H., Zhang, Y., Bai, S., Luo, Y., Han, R., Yang, Z., Cheng, B., Qian, C., & Du, J. (2026) · ACS Nano · doi:10.1021/acsnano.5c22179 · Cited by 3
Kahaer, M., Zhu, Y., He, Y., Chen, W., Yang, D., Du, M., Yang, Q., Chen, X., Sun, Y., & Zhang, B. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1723098 · Cited by 2
HDL anti-inflammatory capacity and residual cardiovascular risk: A prospective cohort study
Jia, C., Wu, W., Xu, X., Xie, Y., Liu, Y., & Chen, J. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.03.015 · Cited by 2
Habib, A., Khan, M. S. M., Aneeq, A., Tahir, H. B., Mehmoodi, A., Malik, J., & Perveen, A. (2026) · Clinical Cardiology · doi:10.1002/clc.70305 · Cited by 2
A Fluorescence-Based In Vitro Method to Assess Cholesterol Efflux
Fernández‐Castillejo, S., Pedret, A., Catalán, Ú., & Solà, R. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1924-7_15 · Cited by 2
Fukase, T., Dohi, T., Nishio, R., Takeuchi, M., Takahashi, N., Chikata, Y., Endo, H., Doi, S., Nishiyama, H., Okai, I., et al. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.09.020 · Cited by 2
Quality control of herbal medicines in hyperlipidaemia: Metabolomics approach
Sajak, A. A. B., Azlan, A., Abas, F., & Hamzah, H. B. (2023) · International Food Research Journal · doi:10.47836/ifrj.30.3.01 · Cited by 2
High-density lipoprotein dysfunction in carotid artery stenosis
Şenat, A., Yön, M. İ., Yüce, G., Denız, O., & Erel, Ö. (2023) · VASA · doi:10.1024/0301-1526/a001082 · Cited by 2
Dyslipidemia in Metabolic Syndrome
Toh, S.-A. E. S., & Lee, M. H. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_58-1 · Cited by 2
Comparing hs-CRP and MPO Biomarkers of Subclinical Atherosclerosis in Metabolic Syndrome Patients
Beautlin, A. J., Govindaraj, A., Devi, D., Ilangovan, G., & Lakshmi, D. (2023) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.17.4.12 · Cited by 2
Li, Z., Fu, C. Y., Sun, C., Suo, Y., Li, K., & Qi, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e31180 · Cited by 2
Maravi, J. S. M., Leszczynski, E. C., Schwartz, C. S., Dev, P. K., Barber, J. L., Reasons, R. J., Pearce, R. W., McPhaul, M. J., Konrad, R. J., Robbins, J., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117587 · Cited by 2
Associations of HDL-C and ApoA-I with Mortality Risk in PCI Patients Across Different hsCRP Levels
Yan, K., Li, J., Zhu, P., Tang, X., Li, Y., Yang, Y., Gao, R., Yuan, J., & Zhao, X. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s465015 · Cited by 2
Exploration of HDL-ome During Pregnancy: A Way to Improve Maternal and Child Health
Zeljković, A., Stefanović, A., & Vekić, J. (2024) · Integrated science · doi:10.1007/978-3-031-64292-0_21 · Cited by 2
Sum, H., & Brewer, A. C. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl26082 · Cited by 2
Li, D., Sun, Y., Han, J., Guo, C., Xia, L., Dou, J., Jiang, W., Deng, J., & Wei, J. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-99003-x · Cited by 2
Wang, X., Li, Y., Cao, Z., Li, Y., Cao, J., Wang, Y., Li, M., Zheng, J., Peng, S., Shi, W., et al. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2491656 · Cited by 2
Monocyte to HDL cholesterol ratio predicts obesity-associated cardiac dysfunction
Zhao, C., Liu, J., Zhao, J., Wang, C., Bai, H., Yang, Q., Ben, J., Zhu, X., Li, X., Jiang, B., et al. (2025) · Journal of Biomedical Research · doi:10.7555/jbr.38.20240432 · Cited by 2
Semler, E. M., Michell, D. L., Kingsley, P. J., Ramirez, M. A., Massick, C., Castleberry, M., Doran, A. C., Carr, J. J., Marnett, L. J., Sheng, Q., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120584 · Cited by 2
Wang, M., Corsetti, J. P., McNitt, S. A., Rich, D. Q., Sparks, C. E., Moss, A. J., & Zaręba, W. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.12.008 · Cited by 2
Genetic control of apoprotein A-I and atheroprotection: some insights from inbred strains of mice
Getz, G. S., & Reardon, C. A. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000442 · Cited by 2
Arun Govind, G., Kamalanathan, A. S., Vijayalakshmi, M. A., & Venkataraman, K. (2017) · Journal of Chromatography B · doi:10.1016/j.jchromb.2017.12.016 · Cited by 2
Nikbakht, M., Nasab, H. A., & Shakerian, S. (2017) · Jentashapir Journal of Health Research · doi:10.5812/jjhr.56079 · Cited by 2
Nachar, W., Merlet, N., Maafi, F., Mihalache-Avram, T., Mecteau, M., Gélinas, D., Shi, Y., Brodeur, M. R., Alem, S., Blondeau, L., et al. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.12.089 · Cited by 2
Metadata
- Authors
- Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- MedStar Washington Hospital Center (US)
- University of California, Los Angeles (US)
- UNSW Sydney (AU)
- Inserm (FR)
- University of Washington (US)
- Columbia University (US)
- University of Kentucky (US)
- Corresponding author
- Rosenson, Robert S.
- Venue
- Nature Reviews Cardiology
- Published
- 2015-09-01
- Volume
- 13
- Issue
- 1
- Pages
- 48-60
- ISSN
- 1759-5002 (ISSN-L)
- 1759-5010
- PMC
- PMC6245940
- OpenAlex
- W2175680864
- Cited by
- 822
- References
- 131
- Citations by year
- 2026: 89 · 2025: 89 · 2024: 66 · 2023: 79 · 2022: 86 · 2021: 79 · 2020: 79 · 2019: 62 · 2018: 69 · 2017: 61 · 2016: 56 · 2015: 5
- FWCI
- 12.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DP3DK108209, P30DK017047)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- HDL dysfunction, atherosclerosis, apolipoprotein A-I, reverse cholesterol transport, ABCA1, ABCG1, myeloperoxidase, nitrosylation, oxidative modification, inflammation, endothelial function, coronary artery disease, atherogenesis, anti-inflammatory activity
- MeSH terms
- Humans, Lipoproteins, HDL, Macrophages, Smoking, Apolipoprotein A-I, ATP-Binding Cassette Transporters, Diabetes Complications, Atherosclerosis, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
